Discussing Phase 1 Findings of Ubamatamab in the Ovarian Cancer Space

David O’Malley, MD, a professor in the department of obstetrics and gynecology at The Ohio State University College of Medicine and the director of the division of gynecologic oncology at the OSUCCC–James, discusses the mechanism of action of ubamatamab (REGN4018) as well as findings from a phase 1 trial (NCT03564340) evaluating the agent in patients with recurrent ovarian cancer.

Within a first-in-human phase 1 study of ubamatamab, a novel MUC16 antibody, a total of 78 patients with recurrent ovarian cancer who had a median number of 4.5 prior therapies (range 1-17) and a median duration of exposure of 12 weeks (range 0.4-117) were enrolled and given treatment with ubamatamab.

According to O’Malley, ubamatamab led to evidence of durable responses and had an acceptable safety profile within this patient population. These findings were presented at the 2022 European Society of Oncology Annual Congress.

Transcription:

0:08 | Ubamatamab is a bispecific antibody, which is directly against the MUC16 and CD3 cells. It brings those immune cells in close proximity to the MUC16 expressing ovarian cancer cells, leading to cell death. MUC16 is expressed in about 80% to 90% of ovarian cancer patients I should say.

0:27 | We presented an efficacy population of those patients who received at least 1 dose at 20 mg or more, which was 42 patients. What we saw were overall response rates of 14%. We looked at the exploratory group of patients that had high MUC16 expression. In the efficacy cohort, there were 13 patients that had that high expression, defined as greater than 75% of tumor cells expressing 2 or more MUC16 IHC. We found a 31% response rate in those 13 patients. That's an exploratory analysis but though that biomarker continues to be developed, it is an exciting option moving forward with ubamatamab.